Evidence map›Paper›PMID 42420469›Full record

GuidelineBone marrow transplantation2026

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Peter Dreger, Gloria Iacoboni, Stephen Robinson, Ali Bazarbachi, Sascha Dietrich, Toby A Eyre, Sairah Ahmed, Timothy S Fenske, Nilanjan Ghosh, Mehdi Hamadani and 5 more

Abstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Peter DregerDepartment Medicine V, University of Heidelberg, Heidelberg, Germany. peter.dreger@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-7429-8570
Gloria IacoboniDepartment of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0805-9288
Stephen RobinsonUniversity Hospital Bristol NHS Foundation Trust, London, UK.
Ali BazarbachiBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Sascha DietrichDepartment of Hematology, University Hospital Düsseldorf, Oncology and Clinical Immunology, Düsseldorf, Germany.
Toby A EyreDepartment of Haematology, Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID http://orcid.org/0000-0002-6631-9749
Sairah AhmedDepartment of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7302-8299
Timothy S FenskeSarah Cannon Transplant and Cell Therapy Program, Methodist Hospital, San Antonio, TX, USA.
Nilanjan GhoshAtrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USA.
Mehdi HamadaniDivision of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0001-5372-510X
Francesco OnidaCo-Chair of the Practice Harmonization and Guidelines Committee of the EBMT, Hematology and BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0002-2991-3474
Annalisa RuggeriCo-Chair of the Practice Harmonization and Guidelines Committee of EBMT and Chair of the CTIWP of the EBMT. Hematology and BMT Unit, IRCCS San Raffaele Hospital, Milano, Italy.ORCID http://orcid.org/0000-0002-7261-2765
Isabel Ortega-SanchezSecretary of the Practice Harmonization and Guidelines Committee of EBMT; EBMT Medical Officer, Barcelona, Spain.ORCID http://orcid.org/0009-0005-5519-9154
Ibrahim Yakoub-AghaChair of the EBMT Practice Harmonization and Guidelines Committee; CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France.ORCID http://orcid.org/0000-0003-4524-8782
Olivier HermineDepartment of Adult Hematology, Necker Hospital, Imagine Institute, Université De Paris-cité, Assistance Publique Des Hôpitaux De Paris, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonisation and Guidelines Committee convened an international expert meeting in Berlin on Sept 29/30, 2025. EBMT provided funding and logistical support. Two appointed chairpersons invited experts in MCL and cellular therapy, who completed three work packages devoted to the three types of cellular therapy. A literature search was performed beforehand and suitable published evidence was considered collectively in structured discussions and consensus-building exercises. The recommendations developed as a result of this process provide a sound basis for practical counseling and decision-making in the care of patients with treatment-naïve and relapsed/refractory MCL.

Indexed as

Cell- and Tissue-Based TherapyHematopoietic Stem Cell TransplantationLymphoma, Mantle-CellHumans

Identifiers

PMID42420469
PMCPMC13569435

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.